Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

EVGN vs SRZN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SRZN Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 7–0 Matrix Metrics)

SRZN Overall Winner 6-Pillar Tally: EVGN 1 – 4 SRZN (1 Tie) Matrix Metrics: EVGN 0 – 7 SRZN

As of Nov 17, 2026, Surrozen, Inc. Common (SRZN) is the stronger overall head-to-head candidate over Evogene Ltd. (EVGN) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EVGN carries a Unified Composite Score of 44.1/100 (HOLD) at $0.34 (N/M Forward P/E, -858.2% operating margin), whereas SRZN carries 46.6/100 (HOLD) at $29.98 (N/M Forward P/E, -485.4% operating margin).

  • Technical & Structure Timing Caution: EVGN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.5); meanwhile SRZN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 52.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EVGN vs SRZN
EVGN NASDAQ
Evogene Ltd.
Agricultural Chemicals
$0.34
-13.17% 1D
Market Cap $6.0M
TTM Revenue $1.7M
Forward P/E N/M
Beta / 30D Vol 1.37β · 138% Vol
Unified Composite Score
44.1 / 100 HOLD
Tech 42.0 Fund 44.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.2%), weak momentum, RSI 44
RSI-14: 44.5 · SMA20: $0.36 · SMA50: $0.40
SRZN NASDAQ Head-to-Head Winner
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$29.98
-7.24% 1D
Market Cap $616.1M
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.29β · 67% Vol
Unified Composite Score
46.6 / 100 HOLD
Tech 40.0 Fund 33.0 Flow 65.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (10.9% over 20 days), RSI 53
RSI-14: 52.5 · SMA20: $29.75 · SMA50: $26.28

6-Pillar Scorecard Institutional Category Breakdown (EVGN 1 – 4 SRZN)

Columns: Metric · EVGN · SRZN
1. Valuation Multiples SRZN
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 49.5x
2. Growth & Scale SRZN
Revenue Growth (YoY) -60.7% +408.6%
Earnings Growth (YoY) +0.0% -37.0%
TTM Revenue (USD) $1.7M $11M
Market Cap $6.0M $616.1M
3. Profitability & Quality SRZN
Gross Margin -67.6% N/A
Operating Margin -858.2% -485.4%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -182.8% -62.8%
4. Balance Sheet & Cash Flow EVGN
Cash Generation (TTM) -$11M -$31M
Cash Flow Margin N/A N/A
Net Cash / Leverage $6.5M Net Cash $95M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SRZN
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 72.0% (5th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EVGN (0) vs SRZN (7)
Institutional Metric EVGN SRZN Criterion Row Edge
Market Capitalization
Scale
$6.0M $616.1M Larger Scale SRZN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-60.7% +408.6% Higher Growth SRZN
Operating Margin (TTM)
Profitability
-858.2% -485.4% Higher Margin SRZN
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-182.8% -62.8% Higher ROE SRZN
52-Week Range Position
Momentum
9% ($0–$1) 69% ($12–$38) Stronger Trend SRZN
Beta / 30D Volatility
Risk Regime
1.37β · 138% Vol 1.29β · 67% Vol Lower Realized Risk SRZN
Unified Institutional Score
Composite Signal
44.1 / 100 (HOLD) 46.6 / 100 (HOLD) Higher Composite SRZN
Trailing 12M Revenue (USD)
Operating Scale
$1.7M $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-67.6% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 49.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$11M ($6.5M Net Cash) -$31M ($95M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SRZN +33.34 pp
EVGN: -7.58% · SRZN: +25.76%
3M Horizon SRZN +68.26 pp
EVGN: -43.4% · SRZN: +24.86%
6M Horizon SRZN +71.54 pp
EVGN: -54.29% · SRZN: +17.25%
1Y Horizon SRZN +202.86 pp
EVGN: -71.89% · SRZN: +130.97%

Financial Trajectory Annualized Quarterly Run-Rate Revenue & Operating Margin Trajectory (USD-Normalized)

Split-Invariant USD Revenue & Operating Margin (%)
Period EVGN Revenue SRZN Revenue EVGN Op. Margin SRZN Op. Margin Margin Leader
Q3 '25 $0M $0M -873.1% -1107.3% EVGN
Q4 '25 $0M $0M -1659.9% -2393.8% EVGN
Q1 '26 $0M $20M -943.1% -209.1% SRZN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EVGN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EVGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SRZN CONSOLIDATION
38d in phase · OBV NEUTRAL
Current IV 72.0%
IV Percentile 5th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact SRZN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EVGN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $6.0M market capitalization and -858.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SRZN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $616.1M market capitalization and -485.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ EVGN vs SRZN Key Questions & Quantitative Answers

As of Nov 17, 2026, Surrozen, Inc. Common (SRZN) is the stronger overall head-to-head candidate over Evogene Ltd. (EVGN) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EVGN carries a Unified Composite Score of 44.1/100 (HOLD) at $0.34 (N/M Forward P/E, -858.2% operating margin), whereas SRZN carries 46.6/100 (HOLD) at $29.98 (N/M Forward P/E, -485.4% operating margin). Technical & Structure Timing Caution: EVGN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.5); meanwhile SRZN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 52.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SRZN leads the Growth & Scale pillar: EVGN posts -60.7% YoY revenue growth and +0.0% YoY earnings growth on $1.7M TTM revenue (-67.6% gross margin, -858.2% operating margin), compared with SRZN at +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin). Across the 3-period historical trajectory (Q3 '25 to Q1 '26), EVGN cumulative revenue shifted N/A while SRZN shifted N/A. In operating R&D and SG&A reinvestment, EVGN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SRZN.

SRZN screens cheaper on headline valuation multiples. EVGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 49.5x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EVGN (-182.8% ROE) versus SRZN (-62.8% ROE) capital efficiency.

In options market volatility and institutional positioning, EVGN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.37β · 138% Vol realized risk). By comparison, SRZN carries 72.0% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.29β · 67% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.